Abstract
Antibody-drug conjugates (ADCs) are currently amongst the fastest growing drug classes in oncology, combining the specificity and targeting capabilities of monoclonal antibodies (mAbs) with the potent cytotoxicity of small molecule drugs. Considered the “biological missiles” of cancer therapy, ADCs are composed of three key elements: (1) a mAb framework that selectively binds to an antigen on the tumor cell surface, (2) a cytotoxic drug payload, and (3) a chemical linker attaching the two entities. Because each of these components can vary widely among ADCs, the associated drug design is relatively complex, with subtle differences leading to immense diversity in the overall drug structure and associated pharmacological and clinical properties. As medical communication experts, it is essential to have a basic understanding of the various components of ADC design and their potential impact on drug efficacy, safety, and capability in targeting certain degrees of antigen expression and tumor types. This review aims to provide a basic understanding of each component related to ADC design and the role they play in defining the therapeutic applications of a particular ADC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
